ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mavacamten

Also written as “Mavacamten” and “MYK-461”.

Its studies are mostly in Cardiomyopathy, Hypertrophic · Anthrax, led by 2 companies.

Drug pageMYK-461: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 27, 202321 company-led studies, 4 open or runningNext primary completion: Dec 13, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb194 open or runningphase 4since Oct 27, 2023Dec 19, 2014Dec 13, 2027phase 4 · NCT07004972
LianBioits history only20 open or runningphase 3since Dec 13, 2021Oct 28, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bristol-Myers Squibb only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Not listed one by one: 5 earlier studies, Dec 19, 2014 to Feb 9, 2018.

  1. Dec 9, 2016Named mavacamtenINNProposed as its International Nonproprietary Name in WHO's List 116 · before, MYK-461
  2. Mar 12, 2018Phase 3 study in Cardiomyopathy, HypertrophicNCT03470545 · 251 enrolled · United States, Belgium, Czechia and more
  3. Apr 5, 2018Phase 2 study in Cardiomyopathy, HypertrophicNCT03496168 · 13 enrolled · United States
  4. Oct 24, 2018Phase 3 study in Cardiomyopathy, HypertrophicNCT03723655 · 314 enrolled · United States, Belgium, Czechia and more
  5. Apr 7, 2020Phase 3 study in Cardiomyopathy, HypertrophicNCT04349072 · 112 enrolled · United States
  6. Feb 16, 2021Phase 2 study in Cardiomyopathy, Familial Restrictive, 3NCT04766892 · 30 enrolled · United States, Canada
  7. Apr 1, 2022Phase 1 study in AnthraxNCT05320094 · 45 enrolled · United States
  8. May 2, 2022Phase 1 study in Cardiomyopathy, HypertrophicNCT05362045 · 158 enrolled · United States
  9. Jun 7, 2022Phase 3 study in Cardiomyopathy, HypertrophicNCT05414175 · 38 enrolled · Japan
  10. Sep 14, 2022Phase 3 study in Cardiomyopathy, HypertrophicNCT05582395 · 580 enrolled · United States, Australia, Austria and more
  11. Jan 31, 2023Phase 1 study in Cardiomyopathy, HypertrophicNCT05719805 · 84 enrolled · United States
  12. Oct 27, 2023Phase 4 study in Cardiomyopathy, HypertrophicNCT06112743 · 63 enrolled · United States, Argentina, Australia and more
  13. Feb 2, 2024Phase 3 study in Cardiomyopathy, HypertrophicNCT06253221 · 44 enrolled · United States, Australia, Canada and more
  14. May 26, 2025Phase 4 study in Symptomatic Obstructive Hypertrophic CardiomyopathyNCT07004972 · 50 enrolled · India
  15. Oct 29, 2026Phase 3 study in CardiomyopathiesNCT07940777 · 500 planned

Ahead

  1. Dec 13, 2027Primary completion: phase 4 study in Symptomatic Obstructive Hypertrophic CardiomyopathyNCT07004972
  2. Jul 21, 2029Primary completion: phase 3 study in CardiomyopathiesNCT07940777

TargetBeta

“Cardiac myosin inhibitor”ChEMBL 37, by rule

Other programs on the same 7 targets

ProgramCompanyFurthest phaseStudies
omecamtiv mecarbilruleCytokineticsphase 316
danicamtivruleBristol-Myers Squibbphase 37

Studies

All 19 Bristol-Myers Squibb leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07940777Cardiomyopathies3Not yet recruitingJul 21, 2029500
NCT07004972Symptomatic Obstructive Hypertrophic Cardiomyopathy · India4Active, not recruitingDec 13, 202750
NCT06253221Cardiomyopathy, Hypertrophic · United States, Australia, Canada and more3Active, not recruitingNov 25, 202544
NCT06112743Cardiomyopathy, Hypertrophic · United States, Argentina, Australia and more4Active, not recruitingJul 16, 202663
NCT05719805Cardiomyopathy, Hypertrophic · United States1CompletedJul 25, 202384
NCT05582395Cardiomyopathy, Hypertrophic · United States, Australia, Austria and more3TerminatedMar 6, 2025580
NCT05414175Cardiomyopathy, Hypertrophic · Japan3CompletedNov 27, 202338
NCT05362045Cardiomyopathy, Hypertrophic · United States1CompletedAug 19, 2022158
NCT05320094Anthrax · United States1CompletedSep 11, 202245
NCT04766892Cardiomyopathy, Familial Restrictive, 3 · United States, Canada2CompletedFeb 26, 202430
NCT04349072Cardiomyopathy, Hypertrophic · United States3CompletedFeb 7, 2022112
NCT03723655Cardiomyopathy, Hypertrophic · United States, Belgium, Czechia and more3CompletedJan 16, 2026314
NCT03496168Cardiomyopathy, Hypertrophic · United States2CompletedNov 9, 202313
NCT03470545Cardiomyopathy, Hypertrophic · United States, Belgium, Czechia and more3CompletedMar 14, 2020251
NCT03442764Non-obstructive Hypertrophic Cardiomyopathy · United States2CompletedJan 7, 202059
NCT02842242Cardiomyopathy, Hypertrophic · United States2CompletedNov 201721
NCT02480296Healthy · Australia1CompletedJul 201660
NCT02356289Cardiomyopathy, Hypertrophic · United Kingdom1CompletedJul 201548
NCT02329184Cardiomyopathy, Hypertrophic · United States1CompletedMar 201615

How it is read

Names in the registry

  • “Mavacamten”, 12 entries
  • “mavacamten”, 5 entries
  • “MYK-461”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.